TY - JOUR T1 - 理解与2型炎症JF不受控制的持续性哮喘的治疗中的关键问题 - 欧洲呼吸杂志JO - EUR呼吸杂志DO - 10.1183 / 13993003.03393-2020 VL - 58 - 2 SP - 2003393 AU - 布斯，威廉W. AU - 卡夫，莫妮卡AU - 拉贝，克劳斯F. AU - 德尼兹，压膜AU - 罗维，保罗J. AU - 拉迪，马塞​​拉AU - 卡斯特罗，马里奥Y1 - 2021年8月1日UR - HTTP：//www.qdcxjkg.com/content/58/2/2003393.abstract n2 - 哮喘是一种复杂的呼吸系统疾病，其严重程度和对治疗的反应变化。已经鉴定了几种具有独特临床和炎症特性的哮喘表型。基于不同分子曲线的内型，有助于进一步阐明哮喘内的异质性。Type 2 inflammation, involving both the innate (type 2 innate lymphoid cell) and adaptive (T-helper type 2 cells) immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease (e.g. chronic rhinosinusitis with nasal polyps, allergic rhinitis and atopic dermatitis). Type 2 inflammation is characterised by upregulation of the type 2 cytokines interleukin (IL)-4, IL-5 and IL-13, IgE-mediated release of immune mediators and dysfunction of epithelial or epidermal barriers. Targeting these key proximal type 2 cytokines has shown efficacy in recent studies adopting a personalised approach to treatment using targeted biologics. Elevated levels of biomarkers downstream of type 2 cytokines, including fractional exhaled nitric oxide, serum IgE and blood and sputum eosinophils, have been linked to mechanisms involved in type 2 inflammation. They have the potential to aid diagnosis, and to predict and monitor response to treatment. The objective of this review is to summarise the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.This review covers the pathophysiology of type 2 inflammation in asthma, its influence on type 2 comorbidities, and ways in which type 2 biomarkers can be harnessed to improve diagnosis and further personalise treatments in the age of biologic medicines https://bit.ly/2MSOI2O ER -